Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
eXalt3: Phase III randomized study comparing ensartinib to crizotinib in anaplastic lymphoma kinase positive non-small cell lung cancer patients. Annals of oncology : official journal of the European Society for Medical Oncology Horn, L., Wu, Y., Reck, M., Wakelee, H., Liang, C., Harrow, K., Oertel, V., Mok, T. 2018; 29 Suppl 8: viii543
View details for DOI 10.1093/annonc/mdy292.121
View details for PubMedID 32137417